Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective

Annals of Surgical Oncology

Volumn 24, Issue 6, 2017, Pages 1722-1730

  Picozzi, Vincent J ^a   Oh, Stephen Y ^a   Edwards, Alicia ^a   Mandelson, Margaret T ^a   Dorer, Russell ^a   Rocha, Flavio G ^a   Alseidi, Adnan ^a   Biehl, Thomas ^a   Traverso, L William ^b   Helton, William S ^a   Kozarek, Richard A ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b St Luke's Mountain States Tumor Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PANCREAS TUMOR; PANCREATECTOMY; PATHOLOGY; PROGNOSIS; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85008210274     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-016-5716-z     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO- 001 randomized trial. JAMA. 2013;310:1473–81.
3. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476–80.
4. Rocha FG, Hashimoto Y, Traverso LW, et al. Interferon-based adjuvant chemoradiation for resected pancreatic head cancer: long-term follow-up of the Virginia Mason Protocol. Ann Surg. 2016;263(2):376–84
5. Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014; 21:1530–37.
6. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.
7. Kim R, Tsao R, Tan A, et.al. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators J Gastrointest Surg. 2010;14(7):1159–69
8. Winter JM, Brennan MF, Tang LH, et.al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19(1):169–75
9. Martin LK, Luu DC, Li X, et al. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. Ann Surg Oncol. 2014;21(3):862–7
10. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.
11. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.
12. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol. 2008;26:3503–10.
13. Clark CJ, Traverso LW. Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg. 2010:199(5):657–62.
14. Hashimoto Y, Traverso, LW Pancreatic anastomotic failure rate is improved after microsurgery. J Am Coll Surg. 2010;211(4):510–21
15. Jacobs AD, Otero HO, Malpass TA, et al. Gemcitabine combined with docetaxel for the treatment of metastatic pancreas cancer. Cancer Invest. 2004;22:505–14.
16. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227–34.
17. Visser BC, Ma Y, Zak Y et al. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxf). 2012;14:539–47
18. Gooiker GA, Lemmens VE, Besselink MG, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014;101:1000–5.
19. Neoptolemos JP, Palmer D, Ghaneh P et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34 Suppl. (abstract no. LBA4006)
20. Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-FU and interferon-alpha-2b-based chemoradiation. Ann Oncol. 2011;22:348–54
21. Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30:4077–83.
22. Hsu CC, Herman JM, Corsini MM et al. Adjuvant chemoradiation for resected pancreatic cancer: the Johns Hopkins Hospital/Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90
23. Bang S, Chung HW, Park SW, et al. The usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastro. 2006;40:923–9.
24. Whittle MC, Izeradjene K, Rani PG, et al. RUNX3 controls a metabolic switch in pancreatic ductal adenocarcinoma. Cell. 2015;161:1345–60.
25. Whatcott CJ, Han H, vonHoff DD. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction. Cancer J. 2015;21:299–306.
26. Jamieson NB, Glen P, McMillan DC, et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer. 2005;92:21–3.
27. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointestinal Surg. 2008;12:1193–201.
28. Dalal S, Hui D, Bidaut L, et al. relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manag. 2012;44:181–91.
29. Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–79.
30. O’Reilly EM, Smith LS, Bendell JB, et al. Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P + Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). J Clin Oncol. 2015;33 Suppl 3 (abstract no. 278).
31. Wang-Gillam A, Li CP, Bodoky G et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;387:545–57.
32. Moore MH, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–66.
33. Hingorani SR, Harris WH, Hendifar AE, et al. High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. J Clin Oncol. 2015;33 Suppl (abstract no. 4006).
34. Le DT, Wang–Gillam A, Picozzi VJ, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CS-207) boost vaccines for metastatic pancreas cancer. J Clin Oncol. 2015;33:1325–33.